Clinical Trial Detail

NCT ID NCT01928394
Title Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

ovarian cancer

stomach cancer

triple-receptor negative breast cancer

pancreatic cancer

lung small cell carcinoma

urinary bladder cancer

Therapies

Ipilimumab + Nivolumab

Cobimetinib + Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST